Cogent Biosciences Inc (COGT)

Currency in USD
10.890
+0.030(+0.28%)
Real-time Data·
COGT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
COGT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.70011.239
52 wk Range
3.72012.970
Key Statistics
Prev. Close
10.86
Open
10.94
Day's Range
10.7-11.239
52 wk Range
3.72-12.97
Volume
639.13K
Average Volume (3m)
2.84M
1-Year Change
25.84%
Book Value / Share
0.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
COGT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
19.273
Upside
+76.98%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Cogent Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Cogent Biosciences Inc Company Profile

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Compare COGT to Peers and Sector

Metrics to compare
COGT
Peers
Sector
Relationship
P/E Ratio
−5.3x−3.4x−0.5x
PEG Ratio
2.68−0.010.00
Price/Book
32.0x2.2x2.6x
Price / LTM Sales
-9.7x3.3x
Upside (Analyst Target)
84.2%200.6%43.4%
Fair Value Upside
Unlock7.0%7.1%Unlock

Analyst Ratings

9 Buy
3 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 19.273
(+76.98% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
-0.5881 / -0.5867
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

COGT Income Statement

People Also Watch

53.28
BMNR
+29.06%
250.69
AVAV
-3.44%
5.38
REPL
-1.84%
7.124
BBAI
+7.77%
3.785
PRME
+2.85%

FAQ

What Stock Exchange Does Cogent Biosciences Trade On?

Cogent Biosciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Cogent Biosciences?

The stock symbol for Cogent Biosciences is "COGT."

What Is the Cogent Biosciences Market Cap?

As of today, Cogent Biosciences market cap is 1.53B.

What Is Cogent Biosciences's Earnings Per Share (TTM)?

The Cogent Biosciences EPS (TTM) is -2.52.

When Is the Next Cogent Biosciences Earnings Date?

Cogent Biosciences will release its next earnings report on 16 Nov 2025.

From a Technical Analysis Perspective, Is COGT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Cogent Biosciences Stock Split?

Cogent Biosciences has split 1 times.

How Many Employees Does Cogent Biosciences Have?

Cogent Biosciences has 205 employees.

What is the current trading status of Cogent Biosciences (COGT)?

As of 08 Aug 2025, Cogent Biosciences (COGT) is trading at a price of 10.89, with a previous close of 10.86. The stock has fluctuated within a day range of 10.70 to 11.24, while its 52-week range spans from 3.72 to 12.97.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.